Compare PURR & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PURR | BHVN |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2025 | 2022 |
| Metric | PURR | BHVN |
|---|---|---|
| Price | $8.74 | $14.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $22.33 | ★ $23.73 |
| AVG Volume (30 Days) | ★ 13.1M | 3.0M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $9,460,000.00 | N/A |
| Revenue This Year | $484.44 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.01 | $7.48 |
| 52 Week High | $14.76 | $18.24 |
| Indicator | PURR | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 52.47 |
| Support Level | $7.85 | $13.56 |
| Resistance Level | $9.04 | $15.82 |
| Average True Range (ATR) | 0.85 | 1.08 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 15.11 | 59.76 |
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to fastest growing revenue pools in digital assets.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.